TearClear Raises $22 Million to Advance Multiple Clinical Programs in Development

UF startup and UF Innovate | Sid Martin Biotech resident client TearClear, a global ophthalmic pharmaceutical company, has raised $22M in a Series B funding round. The investment will be used to advance multiple clinical programs in development, with two lead candidates in glaucoma paving the way for future indications. Participating in the raise was Visionary Ventures, Bluestem Capital, and Flying L Partners, who collaborated with Falcon Vision, a platform formed by KKR to advance innovation in ophthalmology.

The company also announces the appointment of Stuart Raetzman, who most recently served as Chief Executive Officer of Galderma, to the TearClear Board of Directors. “Stuart is a life science industry executive with proven success in pharmaceuticals, biologics, medical devices and over‐the‐counter products. His appointment further strengthens our Board and his commercial expertise will be a tremendous value to the team,” said TearClear CEO, Robert Dempsey.

Learn more about TearClear Raises $22 Million to Advance Multiple Clinical Programs in Development.